For FY2025-26, the revenue and the networth of the mRNA business of Gennova Biopharmaceuticals were Rs 64.71 crore (0.71% of consolidated revenue of Emcure Pharma) and Rs 132.63 crore (2.68% of consolidated net worth of Emcure Pharma), respectively.
The mRNA business business has been divested for a total cash consideration of Rs 139.5 crore. Emcure Pharma expects the transaction to be completed by 17 July 2026.
The company stated that the transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas, which are research and development, manufacturing and marketing of biotechnology-based products including biosimilars and adjacent therapeutic platforms.
Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada.
On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025.
The scrip rose 0.15% to end at Rs 1810.45 on the BSE on Friday.
Powered by Capital Market - Live News
Beware of fraudulent tips, unauthenticated news and advice on stock market.
At BOB Capital, your account security is our topmost priority. Beware of receiving fraudulent communications, unauthenticated trading tips and unsolicited calls on trading in stocks from unverified sources received through WhatsApp, Telegram, SMS, Calls, etc., and take an informed decision before investing.
Report unsolicited messages to the Stock Exchange on +91 8291833676 or email: feedbk_invg@nse.co.in
Please visit here to understand better.
Please visit CVC website at pledge.cvc.nic.in and take "Integrity Pledge" to be an active part of the "Satark Bharat, Samriddh Bharat" (Vigilant India, Prosperous India).
Filing complaints on SCORES - Easy & quick: a. Register on SCORES portal scores.sebi.gov.in/ b. Mandatory details for filing complaints on SCORES are i. Name, PAN, Address, Mobile Number, E-mail ID. c. Benefits: i. Effective communication ii. Speedy redressal of the grievances.
Valued Customer,
BOB Capital Markets Limited (BOBCaps) is firmly committed to the safety of your wealth. We would like to bring to your notice certain precautions that you certainly must take against potential tele-fraudsters/ unscrupulous and unregistered portfolio managers:
ALWAYS AVOID
We would like to caution you against such fraudulent calls and SMSes and urge you to be alert. Follow the golden rule:
Do not share your Login Credentials or Passwords with anybody
BOBCaps employees / representatives never ask for your password.
Certain tele-fraudsters / unscrupulous and unregistered portfolio managers call customers or SMS them on the pretext of providing investment tips and lure them to invest through their bogus firms by promising huge profits.
Such deceitful callers ask the customer to share his/her login credentials with passwords to allow trading in their accounts, assuring huge returns.
Often trades done in the customer’s accounts are far from the best interest of the customers. Holdings of customers are often sold and with the funds, trades are then placed in illiquid securities at unrealistic prices.
At times, the holdings of customers are sold at prices detrimental to the customer. The so-called “portfolio manager” assures profits, which naturally does not materialize. Customers are deceived into providing access to their trading accounts, thereby allowing such fraudsters access to funds and securities available to execute trades, injurious to the customer’s interest.
In our continuous effort to keep you safeguard from the market related frauds and increase awareness while conducting trades, we request you to go through the Press Release issued by the NSE and would request you to ensure that you do not engage with the individuals and entities mentioned below: